Not logged in...
About USC Norris
Research
Patient Care
CISO
Search Trials
FAQ - Trials
Contact Us - Trials
Membership
Education
Shared Resources
Support USC Norris
Outreach
Login/Logout
Contact USC Norris
Support Us
Donate
Menu
USC Norris
»
Clinical Trials
Trial 9L-17-4
Multicenter phase 1/2 Study of Combination Therapy with the DNA Methyltransferase Inhibitor Decitabine and the poly ADP ribose polymerase (PARP) inhibitor talazoparib (BMN 673) for untreated acute myeloid leukemia (AML) in adult patients unfit for cytotoxic chemotherapy or relapsed/refractory AML
Type:
Treatment
Phase:
Phase I/II
Status:
Not Open (Closed)
Treatments:
Other
Randomized:
No
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:
Casey O'Connell, M.D.
Other Trial Staff:
Simbiso Peresuh, Coordinator, Christine Duran, D.M., Ibrahim Syed, D.M., Donna Fernando, Coordinator
Staff may
log in
to see study documents.
Click here to see trial eligibility criteria and further details at ClinicalTrials.gov
For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or
clinical.trials@med.usc.edu
.
To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.